GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
N

Novo Integrated Sciences NVOS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

+33.33%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2024

Revenue

$13.3m

FY2015FY2024

Net income

−$16.1m

FY2015FY2024

Free cash flow

−$2.3m

FY2015FY2024

Shareholders' equity

$14.9m

FY2015FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Revenue$13.3m$12.6m$11.7m$9.3m$7.9m$9.4m$8.9m$8.0m$7.5m$7.5m
Operating income−$8.3m−$8.6m−$25.0m−$4.3m−$4.3m−$785,597−$1.6m−$164,887−$401,573−$572,889
Net income−$16.1m−$13.2m−$33.0m−$4.5m−$4.9m−$391,984−$2.1m−$164,887−$2.8m−$1.0m
Diluted earnings per share-0.85-0.79-0.83-1.66-2.09-0.18-1.01-0.08-1.22-0.48

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Total assets$32.1m$35.6m$71.8m$62.0m$35.4m$32.3m$4.7m$5.5m$27,873$22,592
Cash and short-term investments$844,584$416,323$12.7m$8.3m$2.1m$2.1m$675,705$1.9m$14,123$1,831
Total liabilities$17.5m$11.1m$27.4m$18.2m$5.8m$6.7m$4.6m$9.8m$13,120$648,262
Debt$4.7m$4.5m$19.8m$13.7m$4.4m$5.1m$1.6m$5.5m$6.3m$523,049
Shareholders' equity$14.9m$24.8m$44.4m$43.9m$29.6m$25.6m$201,391−$4.3m$14,753−$625,670
Shares outstanding19m17m40m3m2m2m2m2m2m2m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016FY2015
Cash from operations−$2.2m−$2.2m−$5.9m−$1.0m−$441,694−$822,268−$934,501−$810,687−$175,622−$145,026
Capital spending−$49,224−$49,224−$190,168−$255,949−$12,110−$107,635−$178,626−$38,238−$113,872−$1,000
Free cash flow−$2.3m−$2.3m−$6.1m−$1.3m−$453,804−$929,903−$1.1m−$848,925−$289,494−$146,026
Dividends paid—————————−$12,750

Latest quarters

By quarter end

Nov 2024Aug 2024May 2024Feb 2024Nov 2023Aug 2023May 2023Feb 2023
Revenue$3.1m$3.1m$3.2m$3.2m$3.9m$3.3m$3.3m$2.6m
Operating income−$936,290−$936,300−$2.5m−$1.5m−$3.3m−$3.1m−$1.4m−$1.8m
Net income$5.0m$5.0m−$13.7m−$2.7m−$4.7m−$3.2m−$1.5m−$4.6m
Diluted earnings per share0.260.26-0.72-0.14-0.28-0.19-0.09-0.28
Cash from operations———−$1.0m−$2.0m———
Total assets$32.1m$32.1m$35.3m$34.9m$37.2m$35.6m$35.7m$36.5m
Cash and short-term investments$844,584$844,600$1.5m$651,747$1.6m—$464,011$609,738
Debt$3.2m$3.2m$3.0m$3.7m$3.1m$65,038$2.8m$2.4m
Shareholders' equity$14.9m$14.9m$10.0m$22.2m$23.6m$24.8m$26.6m$27.3m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.6%7.1%—
Operating income24.8%60.3%38.9%
Net income53.5%110.3%33.6%

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-65.2%-98.4%-79.8%—
Net margin-113.4%-142.5%-112.4%—

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return764%-87%42%-55%-27%179%9%338%556%3395%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 10-to-1 reverse split · 7 Nov 2023
  • 10-to-1 reverse split · 1 Feb 2021
  • 20-to-1 reverse split · 5 May 2015

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.